Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study

Claus Roehrborn, Jack Barkin, Steven N. Gange, Neal D. Shore, Jonathan L. Giddens, Damien M. Bolton, Barrett E. Cowan, Anthony L. Cantwell, Kevin T. McVary, Alexis E. Te, Shahram S. Gholami, William G. Moseley, Peter T. Chin, William T. Dowling, Sheldon J. Freedman, Peter F. Incze, K. Scott Coffield, Sean Herron, Prem Rashid, Daniel B. Rukstalis

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Introduction: To report the five year results of a prospective, multi-center, randomized, blinded sham control trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS ) > 12, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume 30 cc-80 cc were randomized 2:1 to the PUL procedure or blinded sham control. In PUL permanent UroLift implants are placed to hold open the lateral lobes of the prostate to reduce urinary obstruction. After randomized comparison at 3 months and the only opportunity to add more PUL implants, PUL patients were followed to 5 years. LUTS severity (IPSS), quality of life (QOL), BPH Impact Index (BPHII), Qmax, sexual function, and adverse events were assessed throughout follow up. Results: IPSS improvement after PUL was 88% greater than that of sham at 3 months. LUTS and QOL were significantly improved by 2 weeks with return to preoperative physical activity within 8.6 days. Improvement in IPSS, QOL, BPHII, and Qmax were durable through 5 years with improvements of 36%, 50%, 52%, and 44% respectively. No difference was seen between Intent to Treat and Per Protocol populations. Surgical retreatment was 13.6% over 5 years. Adverse events were mild to moderate and transient. Sexual function was stable over 5 years with no de novo, sustained erectile or ejaculatory dysfunction. Conclusions: PUL offers rapid improvement in symptoms, QOL and flow rate that is durable to 5 years. These improvements were achieved with minimal use of a postoperative urinary catheter, rapid return to normal, and preservation of both erectile and ejaculatory function. Symptom improvement was commensurate with patient satisfaction. PUL offers a minimally invasive option in the treatment of LUTS due to BPH.

Original languageEnglish (US)
Pages (from-to)8802-8813
Number of pages12
JournalCanadian Journal of Urology
Volume24
Issue number3
StatePublished - Jun 1 2017

Fingerprint

Prostate
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Quality of Life
Urinary Catheters
Retreatment
North America
Patient Satisfaction
Exercise
Population
Therapeutics

Keywords

  • BPH
  • Minimally invasive
  • Sexual function
  • Surgery
  • Surgical therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Urology

Cite this

Roehrborn, C., Barkin, J., Gange, S. N., Shore, N. D., Giddens, J. L., Bolton, D. M., ... Rukstalis, D. B. (2017). Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Canadian Journal of Urology, 24(3), 8802-8813.

Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. / Roehrborn, Claus; Barkin, Jack; Gange, Steven N.; Shore, Neal D.; Giddens, Jonathan L.; Bolton, Damien M.; Cowan, Barrett E.; Cantwell, Anthony L.; McVary, Kevin T.; Te, Alexis E.; Gholami, Shahram S.; Moseley, William G.; Chin, Peter T.; Dowling, William T.; Freedman, Sheldon J.; Incze, Peter F.; Coffield, K. Scott; Herron, Sean; Rashid, Prem; Rukstalis, Daniel B.

In: Canadian Journal of Urology, Vol. 24, No. 3, 01.06.2017, p. 8802-8813.

Research output: Contribution to journalArticle

Roehrborn, C, Barkin, J, Gange, SN, Shore, ND, Giddens, JL, Bolton, DM, Cowan, BE, Cantwell, AL, McVary, KT, Te, AE, Gholami, SS, Moseley, WG, Chin, PT, Dowling, WT, Freedman, SJ, Incze, PF, Coffield, KS, Herron, S, Rashid, P & Rukstalis, DB 2017, 'Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study', Canadian Journal of Urology, vol. 24, no. 3, pp. 8802-8813.
Roehrborn C, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Canadian Journal of Urology. 2017 Jun 1;24(3):8802-8813.
Roehrborn, Claus ; Barkin, Jack ; Gange, Steven N. ; Shore, Neal D. ; Giddens, Jonathan L. ; Bolton, Damien M. ; Cowan, Barrett E. ; Cantwell, Anthony L. ; McVary, Kevin T. ; Te, Alexis E. ; Gholami, Shahram S. ; Moseley, William G. ; Chin, Peter T. ; Dowling, William T. ; Freedman, Sheldon J. ; Incze, Peter F. ; Coffield, K. Scott ; Herron, Sean ; Rashid, Prem ; Rukstalis, Daniel B. / Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. In: Canadian Journal of Urology. 2017 ; Vol. 24, No. 3. pp. 8802-8813.
@article{b6a68f4c4c7e4658bc032324441ca02f,
title = "Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study",
abstract = "Introduction: To report the five year results of a prospective, multi-center, randomized, blinded sham control trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS ) > 12, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume 30 cc-80 cc were randomized 2:1 to the PUL procedure or blinded sham control. In PUL permanent UroLift implants are placed to hold open the lateral lobes of the prostate to reduce urinary obstruction. After randomized comparison at 3 months and the only opportunity to add more PUL implants, PUL patients were followed to 5 years. LUTS severity (IPSS), quality of life (QOL), BPH Impact Index (BPHII), Qmax, sexual function, and adverse events were assessed throughout follow up. Results: IPSS improvement after PUL was 88{\%} greater than that of sham at 3 months. LUTS and QOL were significantly improved by 2 weeks with return to preoperative physical activity within 8.6 days. Improvement in IPSS, QOL, BPHII, and Qmax were durable through 5 years with improvements of 36{\%}, 50{\%}, 52{\%}, and 44{\%} respectively. No difference was seen between Intent to Treat and Per Protocol populations. Surgical retreatment was 13.6{\%} over 5 years. Adverse events were mild to moderate and transient. Sexual function was stable over 5 years with no de novo, sustained erectile or ejaculatory dysfunction. Conclusions: PUL offers rapid improvement in symptoms, QOL and flow rate that is durable to 5 years. These improvements were achieved with minimal use of a postoperative urinary catheter, rapid return to normal, and preservation of both erectile and ejaculatory function. Symptom improvement was commensurate with patient satisfaction. PUL offers a minimally invasive option in the treatment of LUTS due to BPH.",
keywords = "BPH, Minimally invasive, Sexual function, Surgery, Surgical therapy",
author = "Claus Roehrborn and Jack Barkin and Gange, {Steven N.} and Shore, {Neal D.} and Giddens, {Jonathan L.} and Bolton, {Damien M.} and Cowan, {Barrett E.} and Cantwell, {Anthony L.} and McVary, {Kevin T.} and Te, {Alexis E.} and Gholami, {Shahram S.} and Moseley, {William G.} and Chin, {Peter T.} and Dowling, {William T.} and Freedman, {Sheldon J.} and Incze, {Peter F.} and Coffield, {K. Scott} and Sean Herron and Prem Rashid and Rukstalis, {Daniel B.}",
year = "2017",
month = "6",
day = "1",
language = "English (US)",
volume = "24",
pages = "8802--8813",
journal = "The Canadian journal of urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "3",

}

TY - JOUR

T1 - Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study

AU - Roehrborn, Claus

AU - Barkin, Jack

AU - Gange, Steven N.

AU - Shore, Neal D.

AU - Giddens, Jonathan L.

AU - Bolton, Damien M.

AU - Cowan, Barrett E.

AU - Cantwell, Anthony L.

AU - McVary, Kevin T.

AU - Te, Alexis E.

AU - Gholami, Shahram S.

AU - Moseley, William G.

AU - Chin, Peter T.

AU - Dowling, William T.

AU - Freedman, Sheldon J.

AU - Incze, Peter F.

AU - Coffield, K. Scott

AU - Herron, Sean

AU - Rashid, Prem

AU - Rukstalis, Daniel B.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Introduction: To report the five year results of a prospective, multi-center, randomized, blinded sham control trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS ) > 12, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume 30 cc-80 cc were randomized 2:1 to the PUL procedure or blinded sham control. In PUL permanent UroLift implants are placed to hold open the lateral lobes of the prostate to reduce urinary obstruction. After randomized comparison at 3 months and the only opportunity to add more PUL implants, PUL patients were followed to 5 years. LUTS severity (IPSS), quality of life (QOL), BPH Impact Index (BPHII), Qmax, sexual function, and adverse events were assessed throughout follow up. Results: IPSS improvement after PUL was 88% greater than that of sham at 3 months. LUTS and QOL were significantly improved by 2 weeks with return to preoperative physical activity within 8.6 days. Improvement in IPSS, QOL, BPHII, and Qmax were durable through 5 years with improvements of 36%, 50%, 52%, and 44% respectively. No difference was seen between Intent to Treat and Per Protocol populations. Surgical retreatment was 13.6% over 5 years. Adverse events were mild to moderate and transient. Sexual function was stable over 5 years with no de novo, sustained erectile or ejaculatory dysfunction. Conclusions: PUL offers rapid improvement in symptoms, QOL and flow rate that is durable to 5 years. These improvements were achieved with minimal use of a postoperative urinary catheter, rapid return to normal, and preservation of both erectile and ejaculatory function. Symptom improvement was commensurate with patient satisfaction. PUL offers a minimally invasive option in the treatment of LUTS due to BPH.

AB - Introduction: To report the five year results of a prospective, multi-center, randomized, blinded sham control trial of the Prostatic Urethral Lift (PUL) in men with bothersome lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Materials and methods: At 19 centers in North America and Australia, 206 subjects ≥ 50 years old with International Prostate Symptom Score (IPSS ) > 12, peak flow rate (Qmax) ≤ 12 mL/s, and prostate volume 30 cc-80 cc were randomized 2:1 to the PUL procedure or blinded sham control. In PUL permanent UroLift implants are placed to hold open the lateral lobes of the prostate to reduce urinary obstruction. After randomized comparison at 3 months and the only opportunity to add more PUL implants, PUL patients were followed to 5 years. LUTS severity (IPSS), quality of life (QOL), BPH Impact Index (BPHII), Qmax, sexual function, and adverse events were assessed throughout follow up. Results: IPSS improvement after PUL was 88% greater than that of sham at 3 months. LUTS and QOL were significantly improved by 2 weeks with return to preoperative physical activity within 8.6 days. Improvement in IPSS, QOL, BPHII, and Qmax were durable through 5 years with improvements of 36%, 50%, 52%, and 44% respectively. No difference was seen between Intent to Treat and Per Protocol populations. Surgical retreatment was 13.6% over 5 years. Adverse events were mild to moderate and transient. Sexual function was stable over 5 years with no de novo, sustained erectile or ejaculatory dysfunction. Conclusions: PUL offers rapid improvement in symptoms, QOL and flow rate that is durable to 5 years. These improvements were achieved with minimal use of a postoperative urinary catheter, rapid return to normal, and preservation of both erectile and ejaculatory function. Symptom improvement was commensurate with patient satisfaction. PUL offers a minimally invasive option in the treatment of LUTS due to BPH.

KW - BPH

KW - Minimally invasive

KW - Sexual function

KW - Surgery

KW - Surgical therapy

UR - http://www.scopus.com/inward/record.url?scp=85021225450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021225450&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 8802

EP - 8813

JO - The Canadian journal of urology

JF - The Canadian journal of urology

SN - 1195-9479

IS - 3

ER -